LENZ

LENZ Therapeutics, Inc.

NasdaqHealthcareBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Insider activity for last month from Oct 16 to Nov 16.

How these metrics are calculated

Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Total buying$00 buys
Total selling$9.13M3 sales
Net open-market−$9.13MBuying minus selling
Active insiders5Distinct reporting owners

LENZ transaction history

Newest filings · 20 transactions per page

Latest insider transactions

Form 4 filings from last month.
Newest company filings
InsiderActivityDisclosed valueFiled (ET)
Chevallard Daniel R.
Chief Financial Officer
CFO
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
RA CAPITAL MANAGEMENT, L.P.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Cluster sell
At least two distinct reporting owners sold within 14 days, with combined known value of at least $100k.
Repeat seller
The same owner reported more than one sale within 30 days.
+1
Large disposal

Units disposed were at least 25% of reported post-transaction holdings.

SEC filing ↗
−$360kView disclosure →
RA CAPITAL MANAGEMENT, L.P.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Cluster sell
At least two distinct reporting owners sold within 14 days, with combined known value of at least $100k.
Large sale
A sale above $1.0M, or above twice the company’s median insider trade with at least three prior trades in the sample.
+2
Repeat seller

The same owner reported more than one sale within 30 days.

Large disposal

Units disposed were at least 25% of reported post-transaction holdings.

SEC filing ↗
−$1.52MView disclosure →
RA CAPITAL MANAGEMENT, L.P.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Cluster sell
At least two distinct reporting owners sold within 14 days, with combined known value of at least $100k.
Large sale
A sale above $1.0M, or above twice the company’s median insider trade with at least three prior trades in the sample.
+1
Large disposal

Units disposed were at least 25% of reported post-transaction holdings.

SEC filing ↗
−$7.26MView disclosure →

Insider activity report

Calendar-month buckets within the selected date range

Latest filing: Nov 3, 2026

Open-market transaction mix · 3 transactions in the selected period
0 buys0%·100%3 sells

Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.

View exact monthly counts and disclosed values
Monthly activity within the selected period; unknown values remain unknown.
MonthBuysSellsAwards (A)Buy valueSell valueNet P/S value
Oct 2026031$0$9,134,778.24−$9,134,778.24
Nov 2026000$0$0$0

Distinct insiders active

Reporting-owner CIKs by month · peak Oct 2026 (5)
Oct 2026: 5 insidersNov 2026: 0 insiders
Oct 2026Nov 2026
5distinct insiders in selected period
Largest insider activity
By absolute net disclosed value · current transaction page
2 insiders
Filing, role and holdings details
Recent filing activity
Most recent 4 transactions on this page · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy—
Largest sale$7.26M
10b5-1 detected0
Amended rows0

Transaction codes

By Form 4 transaction code in selected period
4transactionstxns
  • S · Open-market sells · dominant3 · 75%
  • A · Grants / awards1 · 25%

Activity by reported role

A joint filing can contribute to multiple roles
10% owner3
Chief financial officer1

Reported Holdings After

Separated by insider, security, and ownership type

Kolchinsky PeterCommon Stock · Indirect · See Footnotes
1.16M243kOct 29, 2026Oct 29, 2026
242,757Oct 29, 2026
Shah Rajeev M.Common Stock · Indirect · See Footnotes
1.16M243kOct 29, 2026Oct 29, 2026
242,757Oct 29, 2026
Kolchinsky PeterCommon Stock · Indirect · See footnotes
57.6k57.6kOct 29, 2026Oct 29, 2026
57,559Oct 29, 2026
Shah Rajeev M.Common Stock · Indirect · See footnotes
57.6k57.6kOct 29, 2026Oct 29, 2026
57,559Oct 29, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells red
2 active days
Oct 16 → Nov 16
LessMore

LENZ Therapeutics, Inc. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at LENZ Therapeutics, Inc.?

Chevallard Daniel R., Kolchinsky Peter, RA Capital Healthcare Fund LP, RA CAPITAL MANAGEMENT, L.P., Shah Rajeev M..

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

RA CAPITAL MANAGEMENT, L.P. reported a sale on Oct 29, 2026 valued at $360k. Read the SEC filing.

What is the recent purchase and sale balance?

Net open-market selling in the selected period was $9,134,778.24. Sales can occur for many non-investment reasons.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.